Keywords |
drug delivery expert, combination product, formulation, applied drug delivery, pharmaceutical research, combination product, drug delivery technology, commercialization, delivery system, devices, life cycle management, stability, patient experience, product profile, biomaterials, molecule properties, target product profile, monoclonal antibody, analytical techniques, commercial potential, PLGA, sustained release, prolonged release, hydrogel, extended release, extended action, ocular, prolonged action, zero order, extended duration, constant delivery, constant release, blood level, patient compliance, drug conjugation, macromolecular conjugates, tailored, proteins, peptides, small molecules, steady-state, platform technology, therapeutics, pharmacokinetics, collaboration, license agreement, consultant, early-stage, preclinical, injection, partner, grants, subcutaneous,
|
Description |
We have over 30 years of diverse experience in polymeric drug delivery systems, stable protein/peptide formulation design, combination product/device delivery, and polymeric biomaterials. Our efforts at Amgen and Ciba-Geigy (now Novartis) led to development of several product candidates useful for the biopharmaceutical, vision care, and agricultural areas. Two of these candidates became marketed products. One is a soft crosslinked polymeric hydrogel contact lens and the other is the long circulating PEGylated protein Neulasta, a multi-billion dollar a year product, which grew out of our site-specific modification know-how.
|